Thursday, December 15, 2011

Ranbaxy Global Consumer Healthcare & Aanjaneya Lifecare Declared Winners In “Neutraceutical Segments” & “Company Of The Year Award” Respectively at 4th Annual Pharmaceutical Leadership Awards 2011

Ranbaxy Global Consumer Healthcare & Aanjaneya Lifecare Declared Winners In “Neutraceutical Segments” & “Company Of The Year Award” Respectively at 4th Annual Pharmaceutical Leadership Awards 2011
Kewal Handa Of Pfizer & Aditi Kare Of Indoco Are Business Leaders While Pfizer, Abbott, GSK, Microlabs, Elder Pharmaceuticals, Fortis, Bharat Biotech, Adriot Are Biomed Among Those Win The Race In Important Categories.
Mumbai : 16th December 2011 : 4th Annual Pharmaceutical Leadership Summit & Awards 2011 ( www.pharmasummit,in ) organized by India’s leading bi-monthly Pharma Magazine ( www.pharmaleaders.co.in ) & IACC culminated in high notes as 23 categories of various Nominations were declared Winners in a sequel to 60 days of votings & Juries final verdict. Among those Companies & Individuals who were declared Winners for their outstanding performance in fiercely competitive India Pharma Market are 1.Business Leader of the Year 2011 : Mr KewalHanda, Managing Director, Pfizer India Ltd. 2.Business Woman of the Year 2011 ( Gen-Next Pharma Leader), MrsAditi Kare Panandikar, Whole Time Director, Indoco Remedies Ltd. 3.Dynamic Entrepreneur of the Year 2011: Dr Krishna Ella, CMD, Bharat Biotech International Ltd. 4.Pharma OTC Company of the Year 2011: Ranbaxy Global Consumer Healthcare. 5.India’s Most Admired Nutrition &Neutraceuticals of the Year 2011, Revital Woman & Abbott Healthcare Pvt Ltd. 6.Company of the Year 2011: Venus Remedies Ltd.7.Pharma CSR Organisation of the Year 2011: Ranbaxy Labs Ltd. 8.Pharma Professional Of the Decade 1.Dr Ajit.V.Dangi, CEO & President, Danseen Consulting. 2. Mr RanjitShahani, Vice-Chairman & MD, Novartis India Ltd,3. Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. 9.Brand of the Year 2011: Revital&Volini. 10.Innovative R & D Company of the Year 2011, Bharat Biotech International Ltd. 11.Emerging Brand of The Year :B-COLEN RANGE of Galpha Labs. 12.India’s Most Admired Foundation in Social Innovation: Right to Vision Programme of Wockhardt Foundation. 13.Pharma Achiever of the year in SME,Dr. Rege's Laboratories.14.India’s Most Admired Company in Blood and Biological Products 2011,Synergy Diagnostics Pvt Ltd. 15.India's Most Admired Pharma Company 2011: Microlabs Ltd. 16.India's Most Watched Company of the Year 2011, Elder Pharmaceuticals Ltd,17. Emerging Company of the Year 2011,AanjaneyaLifecare Ltd. 18.India’s Most Admired Company in Exports 2011:Genom Biotech Pvt Ltd. 19.Research Scientist of the Year 2011: Dr. Rashmi Barbhaiya, MD & CEO, Advinus Therapeutics Pvt Ltd. 20.Multinational Company of The Year 2011. ( Joint Winners)1. Pfizer India Ltd, 2. Glaxo SmithKline Pharmaceuticals Ltd.21.India’s Most Admired Hospital Chain 2011. Fortis Healthcare Ltd. 22.Biotech Research Company of The Year 2011. Adroit Biomed Ltd.23.India’s Most technically & scientifically advanced Pharmaceutical Manufacturing unit of the year 2011. Aanjaneya Lifecare Ltd.
Speaking on the Award Declarations, Mr Satya Brahma, Chairman of Network 7 Media Group said “ Pharmaleaders salute these shining stars who bagged these coveted Awards by a rare display of achievements & performed under a changed healthcare scenario”.
With an aptly theme of Generation Next Indian Pharma Leaders, Billionaire Minds, Drivers for Growth at 4th Annual Pharmaceutical Leadership Summit & Awards 2011, veterans of the India’s Healthcare Industry debated on many topics that grappled Indian Healthcare segments. In an opening address, Mr Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders Magazine ( www.pharmaleaders.co.in ) said “ Indian Healthcare Industry has emerged out as a global super Power & has displayed remarkable display of manufacturing excellence & quality medicines & is way ahead of many developed nations, it is only a matter of time that it will overtake China in coming days, he added. He also lamented at Policy Makers & Authorities for slow decision making process specially in the context of Draft Pricing Policy & FDI in Healthcare Sector & urged the Ministry to hear the voices of the healthcare industry”.
Amonth those who addressed at Asia’s Biggest Leadership Meet are Mr. S. Krishnakumar (KK), Market Leader ( Life Sciences)Future Steps ( A Korn/Ferry Company, Dr Lalit S Kanodia, President Indo-American Chamber of Commerce, (IACC), Western Region, & CMD, Datamatics Ltd. Should drug prices be regulated?Mr. Kewal Kanda, MD, Pfizer India Ltd.` India – An Emerging Pharmaceutical Powerhouse , Dr Ajit V Dangi, Board Chairman, Fulford India Ltd. President & CEO, Danseen Consulting. Dr. Rashmi Barbhaiya , CEO and Managing Director - Advinus Therapeutics Ltd “From Scientist To CEO. The vision: Create a Pharmaceutical company focused on discovering and developing the next generation of high end commercialized medicines.Recent Advancements in Blood & Biological products :Mr Sanjay Bawsay, Managing Director, Synergy Diagnostics Pvt Ltd. Human biotechnology research in India, with emphasis on the BBIL story.Mr. Sai D Prasad, Project Manager - Rotavirus Vaccine Project and Vice President - Business Development. Are FDI & Price Control Policy in Indian Pharma Sector deterrent for growth & Globalize Indian Healthcare Industry. Mr. Shashikant B. Shinde ,Whole Time Director, AanjaneyaLifecare Ltd. Differentiate or Die - Pharmaceutical Industry in India. Mr.DeepakNaik, Managing Director Health 'N' U Therapeutics Pvt. Ltd. MrAnand Desai, National President, IACC & Managing Partner, DSK Legal : Do Pharmaceutical Companies Have Debt Crisis Strategy?. A Legal Perspective. Mr Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. Moving Beyond the Healthcare Debate : The Transformative Trends That Will REALLY Define Our Future. Pharma’s Value Proposition - How The Industry Must Change. Perspectives On Current Industry Challenges .Mr. Sunil Madhok, Director, Business Development, Pfizer India Ltd.
More details of the post event are available on requests at editor.in.chief@pharmaleaders.co.in .

Sunday, December 4, 2011

Watch Pfizer Chief Kewal Handa As He Speaks On His Perspectives of The Controversial Draft Pharma Pricing Policy




Indian Healthcare Industry’s leading voice & one of the most respected name in the pharmaceutical sector, Mr Kewal Handa who strategies world’s leading drugmaker Pfizer in Indian operation will be speaking exclusively via televised tape on how The Centre’s decision to decontrol drug prices would take essential medicines beyond the reach of the common citizen. The controversial policy has been a bone of contention in the industry as there are no takers as the key pharma firms flay ‘populist' draft policy. The draft NPPP-2011 has been circulated among the concerned Ministries/Stake holders asking them for the feedbank.Patented drugs are not defined in the drugs (Price Control) Order, 1995 (DPCO, 1995). Under the provisions of the DPCO, 1995, prices of 74 scheduled bulk drugs and the formulations containing any of these scheduled drugs are controlled. National Pharmaceutical Pricing Authority (NPPA) fixes or revises prices of scheduled drugs / formulations as per the provisions of the DPCO, 1995. Anti-cancer medicines are non-scheduled drugs, i.e. not covered under DPCO, 1995. In respect of non-scheduled drugs, manufacturers are at liberty to fix the prices by themselves without seeking the approval of Government / NPPA. Department of Pharmaceuticals has prepared a draft National Pharmaceutical Pricing Policy 2011 (NPPP-2011) based on the criteria of essentiality and requirements as stipulated by the Ministry of Health & Family Welfare. The draft Policy envisages bringing the National List of Essential Medicines (NLEM) – 2011 and associated medicines under price control. The draft NPPP-2011 has been circulated among the concerned Ministries/Stake holders asking them for the feedbank. This information was given by the Minister of State for Chemicals and Fertilisers, Srikant Kumar Jena in a written reply in the Lok Sabha recently.
Handa speaks exclusively at the 4th Annual Pharmaceutical Leadership Summit 2011(www.pharmasummit.in ) organised by Pharmaleaders ( www.pharmaleaders.co.in ) to be held in Mumbai ob 10th December 2011 via Careworld TV. Mr Handa has strong reservations on the proposed policy as he feels that this will have detrimental effect on the healthcare sector. Kewal Handa is Managing Director, Pfizer Limited, the world’s No.1 pharmaceutical company that discovers and develops break-through drugs, provides information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines, consumer products; and is a global leader in corporate responsibility. Under his leadership, the company is now aggressive in its growth plans and has launched several new products.
Kewal is a reputed industry expert who takes the lead on key issues that concern the pharmaceutical sector. As Vice President of the Organisation of Pharmaceutical Producers of India (OPPI), he has been at the forefront of the industry’s efforts to resolve issues pertaining to the pharmaceutical sector. He is also the Chairman of DPCO & Taxation Committee of OPPI. He has recently been appointed as the President of All India Management Association and is a committee member of various industry bodies in the country. Kewal was awarded the ‘India CFO 2004 – Excellence in Finance in an MNC’ by International Market – Assessment Group and has recently won the Bharat Shiromani Award. A qualified Management Accountant and Company Secretary, and with a Masters Degree in Commerce from Sydenham College, Mumbai, Kewal has completed the Pfizer Leadership Development Program from Harvard University, the Senior Management Development Program from IIM, Ahmedabad. He has also done a course on Marketing Strategy from Columbia Business School. Mr. Handa is also the Managing Director of Wyeth Ltd.

Thursday, November 24, 2011

Management Guru Dr Ajit Dangi to address on India : An Emerging Powerhouse at 4th Annual Pharma Summit 2011

India is also set to become global hub for clinical trials sector. Today India is the most favored destination, fast becoming a signification hub for conducting global clinical trials, contract research, bio-technology. In terms of cost efficiency India is better, as the cost of conducting a trial here is lower by 50-60% than in the United States or the European Union. Key strategic drivers for profitable growth , Including enabling business environment, leveraging Intellectual property as a competitive strategy, building international brands , inorganic growth thru` mergers , acquisitions and alliances, changing paradigm in Pharmaceutical R&D, Biosimilar and OTC Opportunities , making India a Destination of Choice in CRAMS by moving from cost arbitrage to intellectual arbitrage and capitalizing on healthcare reforms in the developed world is what veteran HealthcareManagent Guru is going to address at 4th Annual Pharmaceutical Leadership Summit 2011 at Hotel Lalit on 10th December 2011. India is one of the most significant emerging markets for the global pharmaceutical industry. Moreover, India is expected to join the league of top 10 global pharmaceuticals markets in terms of sales by 2020 with the total value reaching US$ 50 billion, according to a report by PricewaterhouseCoopers (PwC). The domestic pharma market is expected to grow at a CAGR of 15 to 20 percent to reach a value anywhere between USD 50 and 74 billion by 2020, says a PwC report titled ‘India Pharma Inc: Enhancing Value through Alliances & Partnerships’.

The Indian pharmaceutical market is expected to grow to US$ 55 billion by 2020 from the 2009 levels of US$ 12.6 billion, as per a McKinsey & Company report titled “ India Pharma 2020: Propelling access and acceptance realising true potential”. The industry further holds potential to reach US$ 70 billion, at a CAGR of 17 per cent. India’s pharmaceutical industry constitutes of about 8 per cent of the world’s pharmaceutical production. Over the last couple of years, Indian pharma companies have been increasingly targeted by multinationals for both collaborative agreements and acquisition, as per a Espicom report titled, “The Pharmaceutical Market: India Opportunities and Challenges”. The US$ 12 billion valued pharmaceutical industry in India is expected to grow at an annual compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).
India’s exports of drugs, pharmaceutical & fine chemicals stood at US$ 9.26 billion during April 2010–Feb 2011, up 16.15 per cent as compared to US$ 7.97 billion in the same period during the previous year. India’s exports has recorded a growth rate of over 20.07 per cent, during the period of the two financial years in the study, the exports to rest of the world has grown by 9 per cent, according to DGCIS data from Pharmexcil Research. India and Russia signed a memorandum of understanding (MoU) last year. Another will be signed in December 2011, as per Mr Devendra Chaudhry, Joint Secretary, Department of Pharmaceuticals. Indian pharma companies export drugs worth US$ 600 million to Russia every year. Pharma sector accounts for the largest Indian export to Russia. The drugs and pharmaceuticals sector attracted foreign direct investments (FDI) worth US$ 4.89 billion between April 2000 and August 2011, according to the latest data published by Department of Industrial Policy and Promotion (DIPP). Indian pharmaceutical market is predicted to grow to US$ 55 billion by 2020 from US$ 12.6 billion in 2009, according to a report by McKinsey. On back of a high middle-class population base, improvements in medical infrastructure and the establishment of intellectual property rights, the Indian pharma industry is estimated to grow manifold. Generics will continue to dominate the market while patent-protected products are likely to constitute 10 per cent of the pie till 2015, according to McKinsey report ‘India Pharma 2015 - Unlocking the potential of Indian Pharmaceuticals market’. Moreover, as per a press release by research firm RNCOS, the report titled ‘Booming Generics Drug Market in India'. The report further projects the Indian generic drug market to grow at a CAGR of around 17 per cent between 2010-11 and 2012-13. India tops the world in exporting generic medicines worth US$ 11 billion. Currently, the Indian pharmaceutical industry is one of the world's largest and most developed, according to Mr Srikant Kumar Jena, Union Minister of State for Chemicals and Fertilisers. The Pharma market world over will experience substantial changes. Asia-Pacific region is emerging as the fastest growing pharmaceutical market in a recent years. Today, Indian Pharma business is emerging as a global powerhouse with rich pipeline of various products, is becoming 3rd Pharma super power in the international level, despite the current economic slowdown pharmaceutical R&D is increasing mode in India. Industry Insights, reports that the Indian pharmaceutical market, is growing at almost 10 to14 % and valued at Rs.1,00,000 crore currently, it could see the almost double figure in next 5 years. Today Indian Pharma segment will stands at the cusp of a world major out put; exports and contract manufacturing business are growing at 10 % Per anum, and it will contribute to achieve the promised growth in coming years. The Indian pharmaceutical companies export their products (Drug intermediates, APIs, Finished Dosage Formulations, Bio Pharmaceuticals) to more than 200 countries around the world (including highly regulated markets of USA, West Europe, Japan and Australia). 40% of the world’s bulk drug requirement is met by India. As multiple global segments are available for Indian Pharma companies: Such as Pharma manufacturing, drug discovery, research, clinical outsourcing, marketing, and etc. With the increased presence of multinational companies, the Indian pharmaceutical sector is flourishing with multiple opportunities, even the Indian companies are revamping their R&D facilities to comply with World Trade Organization’s Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) agreement and recognized product patents with the amendment of the Indian Patent Act in January 2005.

Steve Hamper
Editorial Director - Pharmanewsprwire
For Registration :
Noble Services
Dimple Arcade, 3rd floor, 314, Asha Nagar,
Kandivali east, Mumbai - 400101. Mr. Sohail Shaikh - +91(0)8888117599
Mr. Mohsin Darvesh - +91(0)810-8120-436
Email : pharmasummit2011@webnoble.co.in
Web : http://www.pharmasummit.in

Wednesday, November 16, 2011

Massive Voting At 4th Annual Pharmaceutical Leadership Award Nominations 2011 Could Spring Surprise Winners

Massive Voting At 4th Annual Pharmaceutical Leadership Award Nominations 2011 Could Spring Surprise Winners
Aditi Kare Of Indoco Remedies With Dr Manu Chaudhary Of Venus Remedies In Close Race For Coveted Business Woman Of The Year. Pfizer, GSK, Elder Pharma, Abbott, Sanofi Aventis, Sun Pharma, Aanjaneya Lifecare Etc Are Hot Favorites At Leadership Awards 2011
Mumbai : 16th November 2011 : As the date of 4th Annual Pharmaceutical Leadership Awards 2011 inch closer to the event date of 10th Dec 2011, the competition for Nominations selected in 25 important categories (www.pharmasummit.in ) getting more & more competitive as large number of Pharma professionals to the tune of 1 million are casting their votes to chose their favourite companies & business leaders. Organized by Pharmaleaders Magazine(www.pharmaleaders.co.in ) & Indo-American Chamber of Commerce ( IACC), 4th Annual Pharmaceutical Leadership Summit attempt to raise burning issues confronted by the Industry. While The Summit will debate on Gen-Next Indian Pharma Leaders with specific emphasis on controversial FDI policy of the Govt as well as Draft Bill of Pricing, The Event is touted to be the biggest conglometer of south-East Asia’s meeting points where Who’s & Who’s of the Healthcare fraternity will assemble to witness to gain the ultimate leadership experience. More than 250 top executives have blocked their calendar for this mega meet.
Originally launched in 1999 as the Pharma Business & Technology Excellence Awards, these were first produced by the PHARMA BUSINESS & TECHNOLOGY MAGAZINE as a means of honoring innovation in pharmaceutical marketing, corporate governance and research and development & Lifetime Achievements category. Pharma Excellence Awards were produced by PBT Awards in India and expanded to recognize global corporate citizenship and individual achievements.As PBT Magazine was discontinued, the task was taken up by the Management of Pharma Leaders Magazine. Over the Years, the awards was re-evaluated and recast to focus more on scientific accomplishments in industry and academic pharmaceutical research. The awards have been presented and at a sold-out gala award night. Since the institution of Leadership Awards, over 200 industry executives and leading academic scientists from around the world have been honoured. Winners have been selected via various processes & judging are based on information provided by the nominees. With the three tier voting process in Email, SMS & Juries verdict, the stage is set for the nominees such as 1. Business Leader of the Year 2011. Dr Habil F Khorakiwala, Chairman, Wockhardt Ltd (Vote HFK to+ 91 9892108169). Mr. Glenn Saldanha, Chairman & MD (Vote GS to+ 91 9892108169). Kewal Handa, Managing Director, Pfizer & Merck Ltd. (Vote KH to+ 91 9892108169). 2. Business Woman of the Year 2011 ( Gen-Next Pharma Leader). Mrs Vinita Gupta, Lupin LTD (Vote VG to+ 91 9892108169). Mrs Aditi Kare Panandikar, Director, Indoco Remedies Ltd (Vote AK to+ 91 9892108169). Ms. Nandini Piramal, Executive Director, Piramal Healthcare Limited, (Vote NP to+ 91 9892108169). 3. Dynamic Entreprenuer of the Year 2011. Dr. GSK Velu, Founder, Trivitron Group of Companies (Vote GV to+ 91 9892108169). Mr K Raghavendra Rao, Chairman & Managing Director,Orchid (Vote KR to+ 91 9892108169). Dhirendra Kumar, Managing Director,Camson Biotechnologies Ltd,(Vote DK to+ 91 9892108169). Dr Krishna Ella, CMD, Bharat Biotech International Ltd ( Vote KE to ++ 91 9892108169). 4.Pharma OTC Company of the Year 2011. Alkem Health Foods (Vote AH to+ 91 9892108169). Elder Pharmaceuticals Ltd (Vote EP to+ 91 9892108169). Abbott Nutrition (Vote AN to+ 91 9892108169). Ranbaxy Ltd ( Vote RAN to – 91 9892108169). 5.India’s Most Admired Nutrition & Neutraceuticals of the Year 2011. Apex Laboratories Ltd (Vote APEX to+ 91 9892108169). Abbott Nutrition (Vote AB to+ 91 9892108169). British Biological (Vote BB to+ 91 9892108169). Novartis India Ltd. (Vote NI to+ 91 9892108169). 6. Company of the Year 2011. Twilight Litaka Pharma Ltd. (Vote TL to+ 91 9892108169). Mankind Pharma Ltd (Vote MP to+ 91 9892108169). Pfizer Ltd (Vote PL to+ 91 9892108169). Abbott India Ltd (Vote LL to+ 91 9892108169). 7.Pharma CSR Organisation of the Year 2011. Ranbaxy Ltd (Vote RL to+ 91 9892108169). Wockhardt Foundation (Vote WF to+ 91 9892108169). Zydus Cadila Ltd (Vote ZC to+ 91 9892108169). Piramal Enterprises. (Vote PE to+ 91 9892108169). 8. Pharma Professional Of the Year 2011 ( No Voting). Dr Kamal Sharma, MD, Lupin Ltd. Dr Ajit V Dangi, President & CEO, Danssen consulting. Mr Ranjit Shahani, Vice Chairman & MD, Novartis India Ltd. 9. Lifetime Achievement Award of 2011 ( No Voting). J.B.Mody, Chairman J.B.Chemicals & Pharmaceuticals Ltd. Pankaj Patel, CMD, Zydus Cadila Ltd. Deepak Pahwa, Chairman, Pahwa Enterprises.10. Brand of the Year 2011. Revital (Vote RE to+ 91 9892108169). Taxim (Vote T+ 91 9892108169). Becosule (Vote BE to+ 91 9892108169). Voloni (Vote VO to+ 91 9892108169). Corex . ((Vote CO to+ 91 9892108169). 11.Innovative R & D Company of the Year 2011. Bharat Biotech International Ltd. (Vote BBIL to+ 91 9892108169). Glenmark Pharmaceuticals Ltd. (Vote GPL to+ 91 9892108169). Zydus Cadila Ltd. (Vote ZC to+ 91 9892108169). Cipla Ltd. (Vote CL to+ 91 9892108169). 12.India's Most Admire Surgeon Of the Year 2011 ( No Voting). Dr Devi Shetty, Chairman, Narayana Hrudayalaya. 13.India's Fastest growing Pharmacy Retail chain 2011. Trust Chemist & Druggist Ltd. ((Vote TC to+ 91 9892108169). Hetero Pharmacy Ltd. ((Vote HP to+ 91 9892108169). Apollo Pharmacy. ((Vote AP to+ 91 9892108169). Religare Pharmacy. ((Vote RP to+ 91 9892108169). 14. Transformational Pharma Leader of the Year 2011 ( No Voting). Dr Surinder Singh – Drug Controller General of India. 15. Excellence Innovators in Blood and Biological Products of the Year 2011. Synergy Dignostic Pvt Ltd. ((Vote SD to+ 91 9892108169). El-Shaddai Biologicals Ltd. ((Vote EB to+ 91 9892108169). VHB Lifesciences Ltd. ((Vote VL to+ 91 9892108169). 16.India's Most Admired Pharma Company 2011. GSK Ltd ((Vote GSK to+ 91 9892108169). Novartis India Ltd. (Vote NIL to+ 91 9892108169). Abbott India Ltd. (Vote ALI to+ 91 9892108169). Glenmark Ltd. (Vote GL to+ 91 9892108169). Sun Pharmaceuticals Industries Ltd.(Vote SPIL to+ 91 9892108169). 17. India's Most Watched Company of the Year 2011. Bliss GVS Pharma ((Vote BGV to+ 91 9892108169). Novartis India Ltd. (Vote NL to+ 91 9892108169). Abbott India Ltd. (Vote AI to+ 91 9892108169). Glenmark Ltd. (Vote GL to+ 91 9892108169). 18.Emerging Company of the Year 2011. Aanjaneya Lifecare Limited ((Vote ALL to+ 91 9892108169). Bliss GVS Pharma . (Vote BGPL to+ 91 9892108169). Lincoln Pharmaceuticals Ltd. (Vote LPL to+ 91 9892108169). Venus Remedies Ltd. (Vote VRL to+ 91 9892108169). Duraent Bilogicals ltd. (Vote DBL to+ 91 9892108169). 19.India’s Most Admired Company in Bulk drugs 2011. Hetero Drugs Ltd ((Vote HD to+ 91 9892108169). Aarti Drugs Ltd . (Vote AD to+ 91 9892108169). Parabolic Drugs Ltd. (Vote PDL to+ 91 9892108169). Aurobindo Pharma Ltd . (Vote APL to+ 91 9892108169). 20. India’s Most Admired Company in Exports 2011. Ipca Labs Ltd. ((Vote IL to+ 91 9892108169). Shreya Life-Sciences Ltd (Vote SLS to+ 91 9892108169). Genom Biotech Ltd . (Vote GB to+ 91 9892108169). Glenmark Ltd. (Vote GL to+ 91 9892108169). Sun Pharmaceuticals Industries Ltd.(Vote SPIL to+ 91 9892108169).21. Research Scientist of the Year 2011. Dr. Rashmi Barbhaiya, MD & CEO, Advinus Therapeutics Pvt Ltd. 22. Multinational Company of The Year 2011. Abbott India Ltd (Vote ABBT to+ 91 9892108169). Pfizer India Ltd . (Vote PIL to+ 91 9892108169). Gsk Ltd (Vote GSK to+ 91 9892108169). Sanofi Aventis. (Vote SAL to+ 91 9892108169). 23. India’s Most Admired Hospital Chain 2011. Fortis Healthcare Ltd. (Vote FH to+ 91 9892108169). Appolo Healthcare Ltd . (Vote AHL to+ 91 9892108169). Max Healthcare Ltd (Vote MAX to+ 91 9892108169). Wockhardt Hospitals . (Vote WH to+ 91 9892108169). 24. Biotech Research Company of The Year 2011. Samarth Pharma Ltd. (Vote SPL to+ 91 9892108169). Indegene Lifesystems Pvt. Ltd (Vote ILP to+ 91 9892108169). Serum Institute of India (Vote SIP to+ 91 9892108169). Avesthagen Limited (Vote AVS to+ 91 9892108169). in 25 categories will be tested & voted.
Registration Contacts for Partcipation :
Noble Services
Accord Group of Companies
Dimple Arcade, 3rd floor, 314, Asha Nagar,
Landmark – Behind Sai Dham Mandir.
Kandivali east, Mumbai – 400101.

Mr. Sohail Shaikh - 08888117599
Mr. Mohsin Darvesh - 0810 8120 436
Email : pharmasummit2011@webnoble.co.in
Web : www.pharmasummit.in

Monday, November 14, 2011

Aanjaneya Lifecare closes on its Acquisition Drive

Aanjaneya Lifecare closes on its Acquisition Drive


Indian Healthcare Sector may soon see Acquisitions in SME sectors as partnership & collaboration will rule the markets. Aanjaneya may acquire a domestic formulation unit to fuel its growth engine.


Maharastra, Mumbai, Tuesday,15th November 2011. Mumbai Based Pharmaceutical Major Aanjaneya Lifecare (BSE code (533412), the largest Quinine producers in world is yet again on the news. Sources close to Pharmaleaders (www.pharmaleaders.co.in ) reveal that Aanjaneya Lifecare is on the final stage of negotiations with a domestic formulation unit to widen its product baskets. Market is abuzz as the news of Aanjaneya posted a rapid strides in its balance sheet with Results for the half year ended for the second quarter ended September 30, 2011, the revenue of the company rose by 39% to Rs 1109 million from Rs 799 million for the same period last year. With this, the total revenue during the first half rose by 36% to Rs 2112 million & the net Profit for the second quarter increased 46% to Rs123 million from Rs 84 million for the same quarter of the previous fiscal year. With this the net profit for the first half of the current fiscal shot up by 51% to Rs. 236 million as against Rs. 156 million for the corresponding period of last year.
If the statement by the Board Chairman Dr Kannan to be believed while addressing the AGM “Our Company has showed an impressive growth in the current year and we promise our investors and stakeholders that we will continue to do the same in future” is to be understood in the right context, one can clearly say that Aanjaneya with focus on anti-malarial, and finished dosage forms (FDFs), has zeroed on a domestic unit with presence in cough cold, pain management segment. It is quite evident as the company in last six months was looking at some established Brands into its product baskets. The size of the Acquisition & deal value & the acquiring company is believed to be kept in top secret as many attempts by Pharmaleaders to reach out the company failed & calls remain unanswered. The News, if to be believed in right context, though unconfirmed officially, could be a game changer for Aanjaneya Lifecare given the aggressive plans the company is looking at to expand.

The company recently raised about Rs. 117 crore from its IPO and the funds are being used to built new capacities alongwith the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed, company sources informed. The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment.

The Author is Editor-In-Chief of Pharmaleaders Magazine. He can be reached at satya.brahma@pharmaleaders.co.in

Saturday, November 12, 2011

4th Annual Pharmaceutical Leadership Summit Gain Momentum

Narayan Gad of Panacea Biotech, Dr. Chandrashekhar Potkar of Pfizer, Dr B.P.S.Reddy of Hetero, Dr. Kannan Vishwanath of Aanjaneya Lifecare, Shailendra Singh of Percept join the Bandwagon to address at 4th Annual Pharmaceutical Leadership Summit 2011
Maharastra : Mumbai,Saturday, 12th November 2011: 4th Annual Pharmaceutical Leadership Summit & Awards 2011 is all set to rock on Saturday, 10th December 2011 at Hotel Lalit Plaza, Intercontinental near Mumbai Airport. a theme to address the growing concerns of the stakeholders. 4Th Annual Pharmaceutical Leadership Summit & Awards 2011 is Asia's leading & prestigious Summit presented & organized by india’s leading Pharma Bi-Monthly PHARMALEADERS in association with Indo-American Chamber of Commerce_IACC), delivering innovative, fully integrated and collaborative approaches to next generation Leadership Issues . This Year’s theme is “Generation Next Indian Pharma Leaders – Billionaire Minds” - Reinventing the Drivers for Growth. Coinciding with the Summit, like each year since 1999, The Event will felicitate some of the outstanding achievers in a star-studded high power-packed gala sold out Award Night.. 4Th Annual Pharmaceutical Leadership Summit 2011 is a CEO / Senior Management level, interactive Summit experience. The Summit speaker faculty are business and scientific pioneers from throughout Europe, US and Asia. Arguably, It is Asia’s most prestigious interactive forum where ideas, intelligence and relationships really make a difference. The Summit attempts to tackles all the key strategic and collaborative issues facing the Pharmaceutical leadership transition and new blend of leadership, both today and in the future over a succinct 1-day programme. The 2011 Pharmaceutical Leadership Summit is where decision-makers from big pharma, early stage and mid stage vaccine biotech, academia, government and regulatory bodies and key industry stakeholders meet to learn and innovate for the future. More than 250 who have & Who’s of the Industry will attend this Summit. The Event will have participation from overseas companies specially from Europe & Middle East.
Widely perceived as the “Event of Substance”, The Summit will have think-tank speakers such as Narayan Gad of Panacea Biotech, Dr. Chandrashekhar Potkar of Pfizer, Dr B.P.S.Reddy of Hetero, Dr. Kannan Vishwanath of Aanjaneya Lifecare, Shailendra Singh of Percept besides Dr Shailesh Iyenger of Sanofi Aventis, Dr. Rashmi Barbhaiya of Advinus Therapeutics, Dr Krishna Ella of Bharat Biotech, Ranjit Shahani, Novartis, Sunil Madhok, of Pfizer Dr Ajit V Dangiof Danseen Consulting, .Deepak Naik, of Health 'N' U Therapeutics, Sunil Madhok, of Pfizer India among those to show lights to Gen-Next Pharma Leaders & debate & deliberate topics of tremendous significance at a time when The Indian pharmaceutical market is poised to grow to US$ 55 billion by 2020 from the 2009 levels of US$ 12.6 billion, as per a McKinsey & Company report titled “ India Pharma 2020: Propelling access and acceptance realising true potential”. The industry further holds potential to reach US$ 70 billion, at a CAGR of 17 per cent.
4th Annual Pharmaceutical Leadership Summit 2011 is aimed at deliberating burning issues confronted by the Industry such as FDI, Pricing etc.
4th Annual Pharmaceutical Leadership Summit 2011
Conclave Secretariat.
Noble Services
Accord Group of Companies
Dimple Arcade, 3rd floor, 314, Asha Nagar,
Landmark – Behind Sai Dham Mandir.
Kandivali east, Mumbai – 400101.
Mr. Sohail Shaikh - 08888117599
Mr. Mohsin Darvesh - 0810 8120 436
Email : pharmasummit2011@webnoble.co.in


Monday, November 7, 2011

Pharmaleaders To Brainstorm On Complex & Uncomfortable Issues At 4th Annual Pharmaceutical Leadership Summit 2011 In Mumbai.

Dr Shailesh Iyenger of Sanofi Aventis, Dr. Rashmi Barbhaiya of Advinus Therapeutics, Dr Krishna Ella of Bharat Biotech, Ranjit Shahani, Novartis, Sunil Madhok, of Pfizer Dr Ajit V Dangiof Danseen Consulting, .Deepak Naik, of Health 'N' U Therapeutics, Dr. Chandrashekhar Potkar, of Pfizer India among those to show lights to Gen-Next Pharma Leaders.

Maharastra, Mumbai, Monday, 7th November, 2011 : The much awaited & talked Leadership event of the year will be staged in Mumbai on 10th December 2011 at Hotel Lalit with the theme “ Generation Next Indian Pharma Leaders – Billioner Minds & Drivers for Growth”. Pharmaleaders, an international Bi-Monthly Magazine ( www.pharmaleaders.co.in ) & Indo-American Chamber of Commerce will host the 4th Edition of Pharmaceutical Leadership Summit 2011 with Pharmaceutical gurus & stalwarts of the Healthcare Sector to stay ahead & get together in a fast-changing, dynamic industry that is estimated to have generated revenue worth US$13.1 billion in FY 2011. India-based companies fulfill around 70 percent of the country’s demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectibles. Come Saturday 10th, December 2011, Policy Makers, Bureaucrats, Pharma Entrepreneurs, Ministers & media will witness Asia’s biggest Annual Affair. Pharmaleaders have roped in the leading voices of the Healthcare & Biotech Sector to address on compex & critical agenda that will set to dictate in next five years. With Indian Healthcare Sector prepared to give reins to the succeeding generations, the stage will be set for intense competition where price control & FDI will be the biggest challenge. The Uncomfortable & complex topics such as Leadership Challenges, The Assassination of Old Guards & Emergence of Brand New Pharma Leaders, Does the Pharma Sector learn how to tackle Debt Controls, Differentiate or Die, Can The GEN-NEXT Indian Pharma Leaders be a Force-Multiplier, Emergence of Biotech Entrepreneurs, The case for personalised medicine,Repositioning of Brand New Leaders are some of the subjects to be debated, discuissed & deliberated by the veterans.
Dr Shailesh Iyenger of Sanofi Aventis, Dr. Rashmi Barbhaiya of Advinus Therapeutics, Dr Krishna Ella of Bharat Biotech, Ranjit Shahani, Novartis, Sunil Madhok, of Pfizer Dr Ajit V Dangiof Danseen Consulting, .Deepak Naik, of Health 'N' U Therapeutics, Dr. Chandrashekhar Potkar, of Pfizer, Anand Desai of DSK Legal, Dr Dinesh Kanodia of Datamatics, Mr Mahesh Zagade of Maharastra FDA are among those to address at the 3rd Annual Pharmaceutical Leadership Summit & Awards 2011. It will be interesting to see how these leaders will reach a consensus on these critical topics of great significance. Coinciding with the Summit, Pharmaleaders will also present the prestigious & coveted 4th Annual Pharmaceutical Leadership Awards 2011 in 25 Nominations currently under voting to above 3 Lacs professionals.

Tuesday, November 1, 2011

4th Annual Pharmaceutical Leadership Awards 2011 Nominations Announced

Habil Khorakiwala of Wockhardt, Kewal Handa of Pfizer, Glenn Saldanha of Glenmark are in the race of Business Leader of the year while Aditi kare of Indoco, Nandini Piramal of Piramal & Vinita Gupta of Lupin are contenders of Next Gen Pharma Business Woman of the Year 2011
Maharastra, Mumbai, Tuesday 1st October 2011 : 4th Annual Pharmaceutical Leadership Awards 2011 is getting bigger & bigger with the latest entry of some of the surprise names entering into the nominations at 3rd Annual Pharmaceutical Leadership Summit & Awards 2011, being organized by Pharma Leaders Magazine ( www.pharmaleaders.co.in ) & Indo-American Chamber of Commerce ( www.iacc.com )to be staged in the commercial capital of Mumbai on Saturday, 10th December 2011 at Hotel Lalit Plaza, Intercontinental, India. Come Saturday, Indian Healthcare Industry will witness some of the brightest stars of the contemporary Pharma leaders as well as emerging Pharma leaders in a star studded event. Coinciding with the day long summit aptly titled theme “ Generation Next Indian Pharma Leaders, Billioner Minds – Reinventing the Growth Drivers”, to be deliberated & addressed by the who’s & who’s of the Indian healthcare industry. 4th Annual Pharmaceutical Leadership Summit & Awards 2011 is industry’s most eagerly awaited event which has institutionalized Leadership Awards in Healthcare industry since 1999.
Being the leading voice of the Healthcare Industry, Pharma Leaders Pharmaceutical Leadership Awards have been widely perceived as the most credible & prestigious. Originally launched in 1999 as the Pharma Business & Technology Excellence Awards, these were first produced by the PHARMA BUSINESS & TECHNOLOGY MAGAZINE as a means of honoring innovation in pharmaceutical marketing, corporate governance and research and development & Lifetime Achievements category. Pharma Excellence Awards were produced by PBT Awards in India and expanded to recognize global corporate citizenship and individual achievements. As PBT Magazine was discontinued, the task was taken up by the Management of Pharma Leaders Magazine. Over the Years, the awards was re-evaluated and recast to focus more on scientific accomplishments in industry and academic pharmaceutical research. The awards have been presented year after year and at a sold-out gala award nights. Over 200 industry executives and leading academic scientists from around the world have been honoured in a moving tribute to their outstanding contributions. 4th Annual Pharmaceutical Leadership Awards 2001 has 24 categories of Nominations with as many as 40 top companies entry into the nominations. Here are the nominees of the 2011 Awards. 1. Business Leader of the Year 2011. Dr Habil F Khorakiwala, Chairman, Wockhardt Ltd (Vote HFK to+ 91 9892108169). Mr. Glenn Saldanha, Chairman & MD (Vote GS to+ 91 9892108169). Kewal Handa, Managing Director, Pfizer & Merck Ltd. (Vote KH to+ 91 9892108169). 2. Business Woman of the Year 2011 ( Gen-Next Pharma Leader). Mrs Vinita Gupta, Lupin LTD (Vote VG to+ 91 9892108169). Mrs Aditi Kare Panandikar, Director, Indoco Remedies Ltd (Vote AK to+ 91 9892108169). Ms. Nandini Piramal, Executive Director, Piramal Healthcare Limited, (Vote NP to+ 91 9892108169). 3. Dynamic Entreprenuer of the Year 2011. Dr. GSK Velu, Founder, Trivitron Group of Companies (Vote GV to+ 91 9892108169). Mr K Raghavendra Rao, Chairman & Managing Director,Orchid (Vote KR to+ 91 9892108169). Dhirendra Kumar, Managing Director,Camson Biotechnologies Ltd,(Vote DK to+ 91 9892108169). Dr Krishna Ella, CMD, Bharat Biotech International Ltd ( Vote KE to ++ 91 9892108169). 4.Pharma OTC Company of the Year 2011. Alkem Health Foods (Vote AH to+ 91 9892108169). Elder Pharmaceuticals Ltd (Vote EP to+ 91 9892108169). Abbott Nutrition (Vote AN to+ 91 9892108169). Ranbaxy Ltd ( Vote RAN to – 91 9892108169). 5.India’s Most Admired Nutrition & Neutraceuticals of the Year 2011. Apex Laboratories Ltd (Vote APEX to+ 91 9892108169). Abbott Nutrition (Vote AB to+ 91 9892108169). British Biological (Vote BB to+ 91 9892108169). Novartis India Ltd. (Vote NI to+ 91 9892108169). 6. Company of the Year 2011. Twilight Litaka Pharma Ltd. (Vote TL to+ 91 9892108169). Mankind Pharma Ltd (Vote MP to+ 91 9892108169). Pfizer Ltd (Vote PL to+ 91 9892108169). Abbott India Ltd (Vote LL to+ 91 9892108169). 7.Pharma CSR Organisation of the Year 2011. Ranbaxy Ltd (Vote RL to+ 91 9892108169). Wockhardt Foundation (Vote WF to+ 91 9892108169). Zydus Cadila Ltd (Vote ZC to+ 91 9892108169). Piramal Enterprises. (Vote PE to+ 91 9892108169). 8. Pharma Professional Of the Year 2011 ( No Voting). Dr Kamal Sharma, MD, Lupin Ltd. Dr Ajit V Dangi, President & CEO, Danssen consulting. Mr Ranjit Shahani, Vice Chairman & MD, Novartis India Ltd. 9. Lifetime Achievement Award of 2011 ( No Voting). J.B.Mody, Chairman J.B.Chemicals & Pharmaceuticals Ltd. Pankaj Patel, CMD, Zydus Cadila Ltd. Deepak Pahwa, Chairman, Pahwa Enterprises.10. Brand of the Year 2011. Revital (Vote RE to+ 91 9892108169). Taxim (Vote T+ 91 9892108169). Becosule (Vote BE to+ 91 9892108169). Voloni (Vote VO to+ 91 9892108169). Corex . ((Vote CO to+ 91 9892108169). 11.Innovative R & D Company of the Year 2011. Bharat Biotech International Ltd. (Vote BBIL to+ 91 9892108169). Glenmark Pharmaceuticals Ltd. (Vote GPL to+ 91 9892108169). Zydus Cadila Ltd. (Vote ZC to+ 91 9892108169). Cipla Ltd. (Vote CL to+ 91 9892108169). 12.India's Most Admire Surgeon Of the Year 2011 ( No Voting). Dr Devi Shetty, Chairman, Narayana Hrudayalaya. 13.India's Fastest growing Pharmacy Retail chain 2011. Trust Chemist & Druggist Ltd. ((Vote TC to+ 91 9892108169). Hetero Pharmacy Ltd. ((Vote HP to+ 91 9892108169). Apollo Pharmacy. ((Vote AP to+ 91 9892108169). Religare Pharmacy. ((Vote RP to+ 91 9892108169). 14. Transformational Pharma Leader of the Year 2011 ( No Voting). Dr Surinder Singh – Drug Controller General of India. 15. Excellence Innovators in Blood and Biological Products of the Year 2011. Synergy Dignostic Pvt Ltd. ((Vote SD to+ 91 9892108169). El-Shaddai Biologicals Ltd. ((Vote EB to+ 91 9892108169). VHB Lifesciences Ltd. ((Vote VL to+ 91 9892108169). 16.India's Most Admired Pharma Company 2011. GSK Ltd ((Vote GSK to+ 91 9892108169). Novartis India Ltd. (Vote NIL to+ 91 9892108169). Abbott India Ltd. (Vote ALI to+ 91 9892108169). Glenmark Ltd. (Vote GL to+ 91 9892108169). Sun Pharmaceuticals Industries Ltd.(Vote SPIL to+ 91 9892108169). 17. India's Most Watched Company of the Year 2011. Bliss GVS Pharma ((Vote BGV to+ 91 9892108169). Novartis India Ltd. (Vote NL to+ 91 9892108169). Abbott India Ltd. (Vote AI to+ 91 9892108169). Glenmark Ltd. (Vote GL to+ 91 9892108169). 18.Emerging Company of the Year 2011. Aanjaneya Lifecare Limited ((Vote ALL to+ 91 9892108169). Bliss GVS Pharma . (Vote BGPL to+ 91 9892108169). Lincoln Pharmaceuticals Ltd. (Vote LPL to+ 91 9892108169). Venus Remedies Ltd. (Vote VRL to+ 91 9892108169). Duraent Bilogicals ltd. (Vote DBL to+ 91 9892108169). 19.India’s Most Admired Company in Bulk drugs 2011. Hetero Drugs Ltd ((Vote HD to+ 91 9892108169). Aarti Drugs Ltd . (Vote AD to+ 91 9892108169). Parabolic Drugs Ltd. (Vote PDL to+ 91 9892108169). Aurobindo Pharma Ltd . (Vote APL to+ 91 9892108169). 20. India’s Most Admired Company in Exports 2011. Ipca Labs Ltd. ((Vote IL to+ 91 9892108169). Shreya Life-Sciences Ltd (Vote SLS to+ 91 9892108169). Genom Biotech Ltd . (Vote GB to+ 91 9892108169). Glenmark Ltd. (Vote GL to+ 91 9892108169). Sun Pharmaceuticals Industries Ltd.(Vote SPIL to+ 91 9892108169).21. Research Scientist of the Year 2011. Dr. Rashmi Barbhaiya, MD & CEO, Advinus Therapeutics Pvt Ltd. 22. Multinational Company of The Year 2011. Abbott India Ltd (Vote ABBT to+ 91 9892108169). Pfizer India Ltd . (Vote PIL to+ 91 9892108169). Gsk Ltd (Vote GSK to+ 91 9892108169). Sanofi Aventis. (Vote SAL to+ 91 9892108169). 23. India’s Most Admired Hospital Chain 2011. Fortis Healthcare Ltd. (Vote FH to+ 91 9892108169). Appolo Healthcare Ltd . (Vote AHL to+ 91 9892108169). Max Healthcare Ltd (Vote MAX to+ 91 9892108169). Wockhardt Hospitals . (Vote WH to+ 91 9892108169). 24. Biotech Research Company of The Year 2011. Samarth Pharma Ltd. (Vote SPL to+ 91 9892108169). Indegene Lifesystems Pvt. Ltd (Vote ILP to+ 91 9892108169). Serum Institute of India (Vote SIL to+ 91 9892108169). Avesthagen Limited (Vote AVS to+ 91 9892108169).
The voting process for the 4th Annual Pharmaceutical Leadership Awards 2011 are through SMS & online polling on the official website at www.pharmasummit.in & the final results will be declared on the 10th Award Night after the summit sessions.

Friday, October 28, 2011

Generation Next Indian Pharma Leaders Is The Theme of Much Awaited 4th Annual Pharmaceutical Leadership Summit & Awards 2011

Mumbai Set To Host The Prestigious Leadership Summit & Awards 2011 organised by Pharmaleaders & Indo-American Chamber of Commerce (IACC) On Saturday,10th December 2011.

Maharastra : Mumbai, Friday, 28th October 2011 : Welcome to the brand new world of Generation Next Indian Pharma Leaders who have risen under the shadow of their visionary fathers & has been instrumental in shaping up the healthcare industry what it is today. A careful analysis of the present leadership transition & succession will reveal that indeed, Indian pharmaceutical industry has been heading for a metamorphosis due to the induction of new way of thinking by the Generation Next Pharmaceutical Pharma Leaders. The evolution of Indian pharmaceutical Sector since independence has been the story of great show of resilience displayed by the patriarchs who dominated Indian pharma sector in reverese engineering & operated under the domain of License Raj till the enunciation of economic liberalization in 1991 under the visionary Finance Minister Manmohan Singh, currently PM. India was exposed to globalization & was thrown plethora of challenges & opportunities. As we embark a full thoughtful analysis of Generation Next Pharma Leaders at Industry’s most eagerly awaited Annual meet “4th Annual Pharmaceutical Leadership Summit & Awards 2011” to be staged by Pharmaleaders ( www.pharmaleaders.co.in ) in association with Indo-American Chamber of Commerce ( IACC)(www.iaccindia.com ) on Saturday,10th December 2011 at Hotel Lalit Intercontinental( Near Mumbai Airport), Mumbai , India under the theme “Generation Next Indian Pharma Leaders” – Challenges & Oppourtunities. More than 30 Industry Leaders will be speaking at the 4th Annual Pharmaceutical Leadership Summit & Awards 2011. The Event being widely perceived as the prestigious Annual Affair, will have participation from Government Academia, Pharma Leaders, Ministers, Social Enterpreneurs.

The first three to four decade of the evolution of Indian Pharma sector saw the visionary legends who scripted the growth story & brought milestone achievements against the powerful MNC’s who continued their move to grab the market share with their high Research-base product range. Late Dr Parvinder Singh of Ranbaxy, Dr Yusuf Hameid of Cipla, I A Modi & Raman Bhai Patel of erstwhile Cadila group, Samprada Singh of Alkem, Suresh Kare of Indoco, Habil Khorakiwala of Wockhardt are some of the notable names that fought against all odds & built-up rapidly their respective empires. While many of the erstwhile regime has changed or diminished or renovated, the new emerging power-equations have come in to fuel the growth engine. “I can say with all confidence & beyond any shadow of doubt that these Pharma Leaders not only mapped the unorganized pharma market but got adapted to the emerging marketing scenario as they changed their Type-Writer to modern day Laptop.While doing so, they went extra miles in Joint Ventures, Acquisitions & Research outlook, leaving a rich legacy to their successors, only time can say that the rich leadership style they practiced in bringing reforms to their own systems, how their sons, daughters & professional designated board will be able to accelerate the pace” says Satya Brahma, Chairman of 4th Annual Pharmaceutical Leadership Summit & Awards & Chairman & Editor-In-Chief of Pharmaleaders Magazine ( www.pharmaleaders.co.in )… Born with silver spoon in their mouth, these billionaire entrepreneurs featured in this story also the others who due to lack of space or unavailability of authentic source of informations have taken the center stage of their growth engine, so far, are struggling with ideas & remain deeply under the shadow & influence of their fathers, as the change from past style to present regime where technological innovations have dominated the space with great speed. Undoubtedly, the foremost fathers of these firms have grown tremendously although we are hearing of class of thoughts & differences of opinions as the companies which was running with one leadership & command has seen the two power-centers & the loyalty of interests has shifted two-fold as the employees try their best to please both father-son duo. While the old school of thought led by the founder clearly have the edge in decision making process but their shadows clearly reflect in the power struggle. Indeed, It has never been easier to go global as Pioneers are using a new generation of support tools to free people from dependency upon particular locations and support mobile activities, relocation and outsourcing. They can transform understanding and make it easier for people to do difficult jobs at any time and any where.. In an era of protectionism international travel and communications were relatively expensive. Today the horizons of ambitious managers embrace the globe. Deregulation, privatization and market forces have eroded trade barriers. Work can follow daylight allowing 24 hour operation. Resources can be accessed and activity undertaken locally, regionally or globally depending upon requirements and comparative costs. Sole traders and jungle natives use websites and email to contact customers all over the world. However, operating in the international business environment also presents new challenges. There are commercial, legal and financial risks to consider. There are obstacles of distance, culture and time to overcome. An investigation in Pharma Leadership has compared the approaches of successful international operators with those of businesses that find it hard going to reveal lessons for those with global aspirations. Thinking global is the first step towards acting global. Be aware of what is happening abroad. Internationalization requires more than an ability to speak foreign languages. Respect other viewpoints. Be tolerant of national differences. Value diversity. Join international project groups, task forces and teams. Seek opportunities for foreign travel, overseas exchanges and job swaps are some of the realities as we embrace the young bloods coming to the centre stage. Companies like countries can have distinct cultures. Indeed, Knowledge of where the best bars are in Cities abroad does not distinguish an ‘international manager’. Attitudes, approaches and perspectives do. Be sensitive to differences and similarities in national assumptions, attitudes, and motivations. Try to reconcile conflicting interests, while recognizing that particular local requirements create opportunities for bespoke offerings.. Customer segments may or may not coincide with national borders. As we find “Experienced international Pharma Leaders are intuitive and cross-culturally aware. Learn to handle diversity and relationships with overseas colleagues. Mutual expectations need to be realistic and compatible. Address practicalities such as whether technologies are compatible.”
As warning comes to us “Don’t be pre-occupied with yourself. Focus on the people you would like to establish, build and sustain relationships with. Understand them. Empathize with them. Respond to their aspirations, hopes and fears. Keeping opportunities to yourself, trusting no one and operating alone will stunt your growth. Form relationships with complementary collaborators. Match your management style to how people you wish to develop closer relationships with operate.”. People need to be properly supported when overseas operations are established. The latest support tools make it easy for people to understand and emulate the superior approaches of high performers. Higher level work can be quickly outsourced and/or moved offshore. Early adopters report better performance, lower costs, speedier and bespoke responses, increased understanding, reduced stress, less risk and enforced compliance. Large returns on investment result. the good news is that there are practical and cost effective ways of capturing and sharing what our Next Generation Pharma Leaders do differently.”
Originally launched in 1999 as the Pharma Business & Technology Excellence Awards, these were first produced by the PHARMA BUSINESS & TECHNOLOGY MAGAZINE as a means of honoring innovation in pharmaceutical marketing, corporate governance and research and development & Lifetime Achievements category. Pharma Excellence Awards were produced by PBT Awards in India and expanded to recognize global corporate citizenship and individual achievements.As PBT Magazine wes discontinued, the task was taken up by the Management of Pharma Leaders Magazine. Over the Years, the awards was re-evaluated and recast to focus more on scientific accomplishments in industry and academic pharmaceutical research. The awards have been presented and at a sold-out gala award night. Since the institution of Leadership Awards, over 200 industry executives and leading academic scientists from around the world have been honoured. At a time when the pharma industry is facing some tough times—and the old way of doing things just won't work, Our Expert Judges roll out the selection methodology to felicitate the top honours. An independent panel of prominent society and industry leaders have been judging these awards. Winners have been selected via various processes & judging are based on information provided by the nominees. Finalists are notified in advance - in writing. The final winners are announced at the awards evening

Tuesday, October 18, 2011

Sahara Shri in problem : SAT orders return of Rs 24,000 cr

Subrata Roy’s Sahara Group, sponsor of the Indian cricket team, owner of the Pune IPL franchise, part-owner of the F1 Force India team and runner of a shadowy business empire that has fallen foul of two regulators, has got its comeuppance at the Securities Appellate Tribunal (SAT).

SAT is where appeals against orders issued by market watchdog Securities & Exchange Board of India (Sebi) are heard.

On Tuesday, SAT told two of Subrata Roy’s companies, Sahara Commodity Services Corporation (SCSC, formerly Sahara India Real Estate Corporation) and Sahara Housing Investment Corporation (SHIC), that Sebi’s 23 June order to return all the money they had collected through optionally fully convertible debentures (OFCDs) stands. They have been given six weeks to comply and return the money.

According to a report, the two Sahara companies will have to return nearly Rs 24,029 crore raised via the OFCD scheme. OFCDs are debentures which investors can convert into shares at their option.

Sahara head Subrata Roy. Reuters



This means SAT has essentially closed Roy’s clandestine and dubious money channel, as ordered by Sebi, even as another channel was closed the Reserve Bank of India earlier. The RBI ordered Sahara to wind down the deposit-taking operations of Sahara India Financial Corporation (SIFC), a residuary non-banking finance company, and the group now claims it will return all deposits by the end of this year.

The Sebi order of 23 June essentially put a stop to Sahara Group’s Ponzi operations of raising money from here and there to run its various businesses. The order, pronounced by former board member KM Abraham, noted that the two companies, which had a minuscule net worth of a few lakh rupees when they started raising money through OFCDs privately in 2008 and 2009, were planning to collect as much as Rs 40,000 crore between them by bypassing Sebi.

As Firstpost noted at that time, “for an OFCD issue involving 6.6 million investors, the issues were to be kept permanently open. Something unheard of in the capital market.”

The Sahara Group challenged Sebi’s right to interfere in the affairs of SCSC and SHIC saying that OFCDs were not under its jurisdiction because they were hybrid instruments – neither shares nor debentures. Sebi’s 23 June order made mincemeat of this argument.

The Sahara Group then tried another tack. It claimed the OFCDs were being privately placed with the Sahara Parivar and not the general public, and hence Sebi should not intervene. But Sebi would have none of it. It pointed out that when OFCDs were being sold to over six million investors, on what basis could Sahara claim these were not members from the general public?

Quite clearly, Sahara Group’s effort was to seek a change in forum since it knew its OFCDs could not withstand Sebi scrutiny. It was obviously hoping to get the ministry of company affairs (MCA) involved on the quiet and get a deal done.

But two things conspired to ruin this gameplan.

One, the Supreme Court ordered SAT to pronounce on the Sahara appeal within eight weeks after involving both Sebi and the ministry. It would have made no sense for two regulatory arms to differ when the Supreme Court running a beady eye on their stands.

But, coincidentally or by deliberate action, the correspondence between the Sebi member (Abraham) and the PMO got leaked – which embarrassed the finance ministry. Abraham complained that the finance ministry under Pranab Mukherjee was seeking to influence the Sahara case – which the ministry vehemently denied. The leakage of this missive from Abraham to the PMO would have tilted the balance against Sahara since any favourable verdict would have looked suspicious.

In fact, the changing political winds became apparent in August when the ministry of corporate affairs, which got initial intimation of the Sahara OFCDs, decided to join hands with Sebi at the SAT hearings.

In an affidavit dated 26 August, MCA said that it had joint jurisdiction along with Sebi to protect investors – and that Sahara’s petition for MCA to hear its case was not tenable. “Both Sebi and MCA work in tandem for protecting (the) rights of small investors. So the question of technicality of jurisdiction is not the way to look at the issue,” says an Indian Express report, quoting the affidavit.

This shift in the MCA’s position is stark since in an earlier affidavit filed with the Allahabad high court in the same case, the ministry had claimed that the registrar of companies under the MCA should have jurisdiction over Sahara, and not Sebi.

But at the SAT hearings, the ministry changed its views. “The Sebi Act is a specialised act and the Companies Act is a basic act. Therefore, the Sebi Act should prevail over the Companies Act,” the MCA is believed to have said in the affidavit.

Once the MCA and Sebi closed ranks, Sahara’s goose was cooked.

Wednesday, October 12, 2011

Indian Affairs of Network 7 Group expands into Online Agency

Network 7 Media Group Media Outfit is a result of emergence of an extreme thought process in the form of some of the biggest & exclusive media properties that arose due to the frustration & disappointment of the present status-quo of the society in existence in the form of a careless & extremely insensitive administration of a large set-up. Network 7 Group has continuously strived to expose the misdeeds of the corrupt administrative fabrics or poor legislation or failure of a large entity in corporate governanance. Distinctively standing out of other media initiatives, Network 7 group has been in the forefront of championing the cause of good governance & fair, unbiased & independent reporting in national & international fields. Driven by the objective to address & deliberate some of the burning issues, sometimes neglected causes, Network 7 Media Group Media Outfit is pioneering the concept of introducing a fierce democratic process in the form a mass resistance in bringing into the forefront of issues that matter most in the form of digital, printed, published, conclaves, summits & even in blogs & letters shoot out to the authoritative.
Headquartered in Mumbai, Network 7 Group Media Outfit is backed & operated by some of the biggest think-tanks of the contemporary society whose ideas & actions are reflected in the form of editorials & exclusive news findings. Network 7 Group Media is present in the form of digital media production, publications, high-profile international events & healthcare communications. Some of the flagship products of the Group are as follows.
PRODUCTS:
1. INDIAN AFFAIRS: www.indianaffairs.in ( Business Magazine quarterly)
The timing of launching Indian Affairs Magazine ( www.indianaffairs.in ), "India’s first ever Pink Magazine on political, business, socio-economic & current affairs from Indian Affairs Pvt Ltd, a flagship Company of Network 7 Group is driven by an objective to bring out ground-breaking true stories to the Indian masses without any interference from lobbyists & corporate houses. The Pink Magazine is present in the form of a digital & print editions. The editorial board of Indian Affairs is composed of journalists in different sections of the society with wide-ranging areas of expertise in business, political, investigative, international & cultural journalism. Their primary responsibility is to write Indian Affairs’s editorials, which represent the voice of the board, its editor and the publisher.
2. PHARMA LEADERS : www.pharmaleaders.co.in ( India’s Most Analytical Bi-Monthly Magazine on Healthcare)
Pharmaleaders,the flagship media outfit of Network 7 Group which also publishes India's leading current affairs pink Magazine "INDIAN AFFAIRS" ( www.indianaffairs.in ) India's leading & arguably one of the best news Magazine in Asia & has over the last one year emerged out as one of the most credible voice with Independent & unbiased reporting in the healthcare industry. Known for its accurate reporting & direct uncomfortable questions to the leading voices of the Healthcare Industry, the objective of the Magazine is to present facts & bring to the limelight the real face of the organization's interface to its internal & external stakeholders. In line with, Corporate ethics & fair governance. Present in the form of Digital & Printed publications, Pharmaleaders is the voice of the healthcare Industry in India. Today Pharmaleaders is a leading title in Healthcare Media both in the form of Digital & Printed Publications. The magazine’s readership includes the top C-level executives, senior industry executives, and key decision makers from the pharma industry in charge of spending. With a special focus on Asia, Pharma Leaders reaches out to the key industry leaders across Asia, Europe and the Americas. Pharma Leaders provides a unique opportunity to bring your products and services to the attention of key budget holders within the largest pharmaceutical organisations around the world. The publication is made available only to a select group of decision makers who represent a spending power of US$ 350 billion. That money is more and more likely to be heading towards Asia and Europe, and you should make sure you get your share. There is a huge market in Europe for Asian products and vice versa. Getting your message across to the major players in these markets is very difficult, unless you have Pharma Leadersand its resources working for you in a consistent manner. Top pharma companies across the world receive Pharma Leadersthat has articles and insights contributed by leading industry experts. The readers of Pharma Leadersappreciate the publication because they recognise the value of its independent reporting and the quality of its content. It clearly makes Pharma Leadersa powerful prospect for advertisers. Published Bi-Monthly with a circulation of circulation of 5,000 copies, Pharma Leadersis distributed across Asia Pacific, the Middle East, Europe and USA. This includes readers who receive the print copies and another 75,000 readers who receive e-book copies. This translates into an estimated readership base of 125,000. Our readers represent the most important organisations in the global pharmaceutical market, and they should be your target market, because your competitors are already targeting them. Pharma Leadersprovides customised advertisement solutions through high quality advertisements placed along side relevent content to receive immediate attention from your target market. Pharma Leaders, with its total commitment to building exceptional circulation lists, can deliver your message to the right people. Our relationship officers can help you in your marketing plan with highly targeted advertising, aimed directly at the people who hold the purse strings.
 Circulation: A meticulously crafted circulation database of companies that matter to you – A market place custom-built to your needs.
 Readership: Readers are carefully chosen top executives. A judicious blend of purchase decision makers and specifiers - the individuals who matter most to your company.
 Valuable Content: Insights and incisive analysis of industry dynamics and emerging trends in technologies including drug discovery, manufacturing etc., written by the leading experts.
 Online Presence: Listing on the search engine optimised website - Print advert doubling-up as online vehicle.
3. PHARMANEWSPRWIRE : www.pharmanewsprwire.com . India’s Premier Pharma News Agency
Pharmanewsprwire is India's Only Pharma Press Distribution Newswire Agency that address the needs of disseminating informations to the targeted audiences. Pharmanewsprwire is a vibrant platform of knowledge sharing & dissemination of informations on the latest trends, news & analysis of the entire gamut of the healthcare industry.Behind the infrastructure of pharmaprnewswire.comand its powerful database of thousands of Pharmanewsprwire is a dedicated team of experts in all aspects of media communications.Our people are highly experienced journalists, editors and publishers, with high-profile media careers on leading newspapers and magazines around the country.We keep our finger on the pulse, keeping up to date with movements across the industry so our database is as current as possible.
This is helped by the fact that a number of our team continue to contribute to major newspapers, magazines and internet sites, and also undertake sub-editing roles on metropolitan daily newspapers.They are therefore highly skilled in both copywriting and editing, and have an insiders understanding of what makes a good story that will be of interest to the media.In addition, because they have such a depth of experience in the media and the way it functions, they are also regularly called upon by government departments, corporations and other organisations to conduct hands-on workshops on understanding and dealing with the media.If this is an area that interests you, pharmaprnewswire.comis very well placed to assist in tailoring a media skills development program to fit your specific needs.Contact us now for an obligation free appraisal of your media relations and media skills development needs. We believe that the most effective campaigns are those in which your input is encouraged and respected. With more than 15 years of experience, we have developed winning strategies to ensure your news gets noticed. We implement the latest publicity tools for each client to create a campaign that is custom designed for your specific needs. We are results driven. We will work with you to create a book publicity campaign and even schedule speaking engagements to maximize every appropriate media opportunity for your book. Each project draws on the extensive experience of our publicity team and is targeted to reach some of the nation’s top reporters, editors, producers, meeting planners and bloggers. We can't sleep if we believe there is an aspect of your campaign that isn't covered. What we Do & What we Don’t Do?. The Big Picture.We’ve been in your seat. Questioning which is the best and most cost-effective media to use. Wondering when it is time to try something new. Determining how to reach a new market. Curious about your target audience.
Pharmanewsprwire is equipped to:
 Find the subtle nuances of each market and use those to zoom-in on, and effectively target your specific audience
 Evaluate media efficiencies
 Help you stay ahead of the new media curve
 Explore new markets
 Guide you through the market analysis process
The Breakthrough. Ah! The great advertising dilemma. How do you know if your message is breaking through the cluttered advertising environment to reach your target audience and how often? At Target Media, we define media as any medium that may be used to promote brand, image and/or message. Based on extensive research and experience, our media specialists can identify, negotiate and place any traditional or new media opportunities that help to accomplish your campaign goals, including:
 Television
 Radio
 Print
 Outdoor
 Website
 Pay-Per-Click
 Direct-to-Door
 Direct Mail
 Text Messaging
 Cinema
 Sports Partnerships
 Transit
 And more...
Target Media’s custom reporting system:
o Shows you how much of your target audience your overall campaign is reaching and how often (unduplicated Reach & Frequency)
o Takes the guesswork and wasted spending out of advertising
o Provides an easy-to-follow plan from production to flight dates
 The Back-up. You have a plan, so now what? Deciding how and where to spend your advertising dollars is only part of completing the media puzzle.

Pharmanewsprwire fills in all the pieces by:
o Placing and confirming your campaigns with each media outlet
o Negotiating added-value as part of every buy to further maximize your share of voice and extend your ROI
o Coordinating and trafficking your creative with each media outlet
o Verifying your media buys to ensure that stations deliver as promised through a Post Buy Analysis
 The Bottom Line. Admit it, isn’t that the driving force behind advertising? Regardless of whether your perspective is increasing overall profitability; balancing a budget or achieving a specific goal. At Pharmanewsprwire, we:
o Listen to your goals
o Analyze your budget
o Recommend a media mix to help you effectively and efficiently engage your target consumer
o Provide solutions to grow your bottomline and maximize your return on investment
o It's an exciting time. Even now, as Facebook, YouTube, and Twitter make way for Google+, Google Buzz, BlogFrog, and location-based platforms like foursquare and Loopt, we still haven't arrived at a definitive answer to the question: “What can we do with social media?” Its reach and potential continue to grow, providing seemingly endless opportunities to help clients engage with stakeholders.
o However, in the land rush for social media real estate, we've seen some companies jump to adopt the cool tools before doing the hard work of understanding the audiences, the business objectives, and the quantitative and qualitative metrics that will define success. Driving a well-honed strategy to the total communications effort, including social media channels, is a critical way for bona fide PR firms to bring true value to our clients.
o While we realize the value of kicking the tires of new social services at Linhart Public Relations, we're not losing sight of the most important thing we can offer our clients: strategic thinking and insight that helps clients chart a course for social media success.
o While aligning digital media strategy with clients' business objectives is job one, it is also key to understand and align with their corporate culture. Social media tactics must reflect the brand or company voice and resonate with the community of stakeholders. If transparency and authenticity are lacking, and the communication comes across as billboard clichés rather than dialogue among real people, there's little point in pursuing it. If companies adopt social media merely to get hits, likes, and smiley faces, it's a wasted effort.
o With each digital media success for our clients, we are advancing our expertise and contributing to the industry's social media body of knowledge, but the specialization in big-picture counsel has always been — and will continue to be — our sweet spot.
o Today, we are continually experimenting with the “shiny objects” that seem to emerge weekly from the imaginations of social services developers, while keeping our focus on long-term brand- and reputation-building strategies. The more things change, the more they stay the same.
 We provides strategic communications programs that leverage clients’ unique attributes to build strong brands and produce measurable ROI. We draw on deep experience, insights, and relationships to provide fresh thinking, clear and compelling communications, and access to leading media, conference organizers and influencers. Our aggressive hands-on implementation of corporate communications programs help clients raise awareness with customers, shareholders, employees, analysts and the media, and ultimately, grow their businesses. We are committed to delivering flawless execution and impeccable service, and to developing long-term client relationships.
1. Focus: Pharmanewsprwire focuses specifically on working with financial and professional services firms.
2. Experience: Pharmanewsprwire’s professionals have decades of experience as public relations and marketing professionals, journalists, and designers.
3. Connections: With our focus and experience, Pharmanewsprwire has developed strong ongoing relationships with the top business print, broadcast and online journalists, as well as conference organizers, associations, exchanges and business schools.
4. Strategy: Pharmanewsprwire is well regarded for its creative and strategic thought leadership initiatives that leverage multiple mediums to shape and tell clients’ stories in the context of financial services trends and issues.
5. Results: As our clients will attest, Pharmanewsprwire is a trusted partner that delivers high-quality news coverage, marketing materials, websites and advertisements that help them grow their businesses.
Our philosophy is to fully understand the goals and resources of our clients and to develop integrated branding, marketing and public relations campaigns that shape and leverage their attributes to help them achieve their overall marketing and business objectives. We strive to be strategic, proactive, creative, informed and engaged and always to deliver the highest quality results. Our clients often say they view Pharmanewsprwire Communications as an essential part of their team.
We believe in the power of integrated campaigns that include media relations, conference speaking, sponsorship, direct mail, advertising, e-mail campaigns, social media, and website communications and optimization.
Our approach is to help our clients drive new business through marketing and public relations by:
1. Understanding their business goals.
2. Shaping their brand messaging to position them as possessing the services needed to help their clients succeed.
3. Developing creative, compelling and consistent marketing communications programs.
4. Leveraging research and insights tying the client’s expertise to timely industry trends and issues.
5. Providing media training, and enlisting and accompanying key spokespeople to meet and speak with targeted journalists.
6. Engaging proactively with the media and your clients and prospects.
We are Effective, Results-Oriented, Original Brains
We’re not baking cookies at Pharmanewsprwire. Every solution we create is customized to your needs; and the recipe is different for every client we work with. But, all our strategic communications and public relations programs include some of the same ingredients: We start with a healthy dose of Original Brains. We take the time to understand what our clients’ goals are and then apply the ‘secret sauce’ that comes with the right combination of experience, technique and creativity.
Next, we spice all our PR and communications solutions with the right mix of Skillful Storytelling, specifically designed narratives to engage your target audience and encourage interaction with and adoption of your brand. We open minds. Then, we bake in a 360-degree Approach to getting the word out, a tasty combination of classic PR solutions and new media communications strategies. And finally, we test the success of each public relations and communications program through the rigorous application of Measurement & ROI Analysis. At Graham & Associates, our custom recipes create brand appetite appeal. We’ve got all the ingredients to awaken audience hunger with something substantial and satisfying, no junk food. And, no cookie cutters allowed. It’s said as humans, we use only 10% of our brains. Not here, we don’t. We approach each public relations and communications campaign with a fervent search for originality. We discover what will make your organization stand out, get noticed, and receive the PR, buzz and attention you deserve. At Graham & Associates, our Original Brainsis about harnessing authentic brand character, developing powerful messaging and tapping trends and conversations in the current environment to arrive at the strategic intersection of “what matters” to accelerate positive brand and PR outcomes. It’s tough to break through in today’s oversaturated, always-on communications environment, but we do it time and again by developing campaigns that connect with your audiences. Our firm’s approach allows us to move faster, focus on effective outcomes, provide measurable results and deliver consistent value for our clients.
Original Thinking. It’s where smart PR and communications start.
At Pharmanewsprwire, we believe the heart of successful communications and public relations lies in the art of skillful storytelling. Since time began, stories are how humans have connected. It’s simply the how, where and speed of storytelling and the competition for our mindshare that have changed. Today, telling the right story at the right time in the right place to reach the right audience is the key — whether it appears in a short YouTube video, magazine feature, television broadcast or social network conversation string. With Original Brains, we uncover the fresh, essential story that expresses what really matters — often in a way that hasn’t been considered before. It starts with developing a clear and compelling message, then shaping a narrative and choosing a platform that will engage your audience and break through today’s information clutter. Want to move your brand faster into the minds and dialogue of your constituents?
We can help. Your story is our business.
At Pharmanewsprwire, we understand the importance of using every available channel to get your message out. Here, traditional approaches are augmented with new and innovative PR strategies. We explore all alternatives. But, we never allow our embrace of emerging communication channels to distract us from choosing the right ones to tell an authentic story that builds your brand. Today, there are no places to hide. As media and communication methods keep changing, online and social media initiatives affect your brand offline and vice versa. It’s now truly a 360-degree seamless experience. Audiences touch and interact with your company everywhere, every day and in every way. Yet, messages must remain consistent across all PR, communications and the user experience.
We consider this reality in crafting our Original Brainscommunications and PR campaigns. Our agency gets to the essential message, removes the clutter surrounding it and encourages your audience’s deep engagement via traditional and emerging platforms, all with your reputation in mind. Measuring ROI and the impact of a public relations or communications program is important to marketers and even more so to the C-suite. We help you speak that language. Pharmanewsprwire’s in-depth measurement programs give marketers a true picture of success. Our QuantifyPR advanced customizable measurement suite is available to measure communications and PR results against business objectives and aids in more effective campaign planning. We empower marketers with critical data to help you answer questions from upper management, investors and boards. Our measurement suite provides traditionally used quantitative metrics, i.e., outputs, as well as more sophisticated analyses of the qualitative factors, i.e., outtakes (what audiences understood) and outcomes (quantifiable changes). We can analyze programs at many levels, meeting different organizational needs such as increase in brand awareness, brand recognition, sales conversion rate, share of discussion/voice, category establishment and finally return-on-investment on PR. These services are customizable to meet your specific needs and budget.
Shouldn’t the bottom line of any public relations program be results? At Graham & Associates, we think so. Consumer-driven healthcare. Demands for transparency. Competition from unlikely places. All playing out in a highly regulated environment -- that is the landscape that must be navigated by firms competing in today's healthcare industry. In every major international market, Pharmanewsprwire is helping pharmaceutical firms, hospitals, medical associations and medical device manufacturers navigate this complex environment. Our communications programs draw on Pharmanewsprwire's broad global reach and expertise in media relations, issues management and brand marketing and communications, as well as related specialties like diet and nutrition and health and beauty.
One of the reasons that many leading healthcare companies and most of the top 10 pharmaceutical firms choose to work with Pharmanewsprwire is our unmatched ability to assemble teams combining global talent with feet-on-the-street specialists who are fluent in the local language and healthcare environment. Our award-winning campaigns span a range of therapeutic categories, including men's and women's health; infectious diseases; critical care including oncology, pain management, and emergency medicine; and chronic disease including diabetes, asthma, and cardiology. Although we like to dive deep into the science of healthcare, we also see the big picture, too. As part of that larger healthcare landscape, Pharmanewsprwire is one of the few agencies that can assemble networks of external influencers from diverse disciplines -- regulators, healthcare services providers and consumers -- to garner insights that provide a valuable outsider's view of our clients brands. Pharmanewsprwire's passion for healthcare issues goes beyond conventional client-agency relationships. Our belief in the urgent need to improve world health is put into action through pro bono services around the globe. For example, Pharmanewsprwire works with the World Economic Forum's Global Health Initiative to help them combat AIDS, TB and malaria in developing countries.
Healthcare companies and associations transform lives. Pharmanewsprwire's deep understanding of this complex industry and global collaborative community ensures that our clients have a strong voice in the worldwide dialogue about healthcare and its power to change people's lives.
Creating legacies … one brand at a time—it’s what drives us.
We call our Client Service “AN EPIC,” which provides insight into how we work, what we value and how we think about public relations practice. After all, an epic can be a long story, a heroic poem, a legend or a legacy (and we have a long history of producing breakthrough work for satisfied clients with lasting results), but it also expresses a dedicated commitment to greatness. Our Code encourages us to constantly innovate and improve upon best PR practices. In today’s slang, to be absolutely awesome. At the end of the day, it all comes down to results. With more than 50 awards in the past seven years, we must be doing something right. But we’re not resting there. We know that our success is rooted in yours. Creating legacies … it’s what drives us.
USING PHARMANEWSPRWIRE WHAT YOU GET?
 Promote Your Business on Manta
 Add your company profile to Manta. It's FREE.
 Upgrade to a Premium Listing
 Move your profile to the top of Manta search results.
 Enhance Your Manta Profile
 Best practices for creating & improving your profile.
 Connect With the Community
 Share ideas with business owners on Manta Connect.
 Get Answers
 To frequently asked questions about Manta.
 See How Your Business Ranks
 Chart companies by industry & geographic area.
 Manta Mobile
 Access Manta search on your mobile device.
 Find Newly Formed Businesses
 Thousands of new businesses are added every week.
 Refine Your Search Results
 Use Manta filters to get right to the info you want.
 Find a Job
 Search millions of jobs by category and location.
 Learn From Business Videos
 Thousands of videos to help you grow your business.

4. INDIA LEADERSHIP CONCLAVE ( www.indialeadershipconclave.com ) (www.indialeadershipconclave.in ) (www.ilcbusinessleaders.com )

Business Leadership Award 2009 and the winner are:

Revolutionary Leader
of Modern India

Late
Shri Rajiv Gandhi


Lifetime Achievement Award

Ratan Tata
Chairman
TATA Group


Lifetime Achievement Award

K.V. Kamath
Chairman
ICICI Bank Ltd


The India Corporate Citizen of the Year

Mukesh Ambani
Chairman
Reliance Industries Ltd


India’s Best Airline

Dr. Vijay Mallya
Chairman
UB Group




Young Business Leader

Uday S. Kotak
Executive Vice Chairman & MD
Kotak Mahindra Bank


Brand of the Year

Lalit Kumar Modi
Chairman and Commissioner
IPL


Business Women
of the Year

Ms. Chanda Kochhar
CEO
ICICI Bank Ltd


Bank of the Year

M.D. Mallya
CMD
Bank of Baroda


India’s most
Admired Bank

O.P. Bhatt
Chairman
SBI Bank




India's most Promising Web-based
Solutions Company

Pankaj Jaiswal
Chairman/MD
Dotcom Services (I)
Pvt Ltd

Lifetime Achievement
Award

Yash Chopra
Producer, Director
Yash Raj Films

India’s Upcoming Biogroup CO.

Sanjay Bawsay
Chairman
Synergy Diagnostics
Pvt Ltd

Innovation in Blood Products in IV/IG

R. Muthukrishnan
Chairman
Elshaddai Biologicals Ltd

India’s most Admired Electronics Brand

Venugopal N. Dhoot
CMD
Videocon Industries Ltd



Technically & Scientifically Most Advanced Biotech Company

Gunvantlal Shah
Chairman
Samarth Pharma Pvt Ltd


Upcoming Pharma
retail chain

Hemant Bothra
MD
Trust Chemists & Druggists


Yongest & Dynamic Enterpreneur Award

Nikunj Kirtibhai Kanakia
Chairman/MD
Lifeline Industries Ltd


Infrastructure Co.
of the year

Sanjay Reddy
Vice-chairman of GVK Industries &
MD of Mumbai International Airport Ltd

CSR Woman
of the year

Ms Sudha Murthy
Chairman
Infosys Foundation


in a star-studded, power-packed audience followed by outstanding presentations from the think tanks of India, 2nd Annual India Leadership Conclave 2011(indialeadershipconclave.com) & Indian Affairs’s Business Leadership Awards 2011 ( www.indianaffairs.in ) organized by Indian Affairs & Indo-American Chamber of Commerce concluded at Hotel Nootel, Mumbai, India on 22nd April with business Leaders & Companies were honored with coveted Awards. The Nominations in various segments was marked by votings & sms campaigns to choose their Leaders. The suspense got over when the Awards were declared by the Chief Guest of the Evening by Shri Sanjay Nirupam, Member of Parliament, Government of India & AICC Secretary who gave away the Awards to the winners. Speaking at the Conclave, Nirupam while congratulating the Winners urged the industry “to come forward & be a part of catalyst of change. He further added that the Nation need their services to take Indian Industry to the global map” .
Those who were awarded are India’s Most Admired Private Bank – Yes Bank Ltd., India’s Most Admired Public Bank – Bank of Baroda. ,India’s Most Promising & Admired Infrastructure Company – MARG GROUP. India’s Most Admired 4 Wheeler Company- Fiat India Automobiles Limited. BusinessLeader of the Year – Malvinder Mohan Singh, Chairman, Fortis Group., BusinessWoman of the Year : Naina Lal Kidwai: Country Head India , HSBC. India’s Best Managed Hospitality Group : Alila Diwa Goa Hotel, India’s Most Promising IT & Web Solution Provider Company : Dotcom Services India (P) Ltd, & General Data Pvt Ltd. India’s Most Admired & Best Managed Medical Tourism Company – Fortis Healthcare Ltd., Innovative CEO of The Year – G.R.K.Reddy, Chairman, Marg Group., Excellence in Social Service – Marg Parivarthan. India’s Dynamic Entrepreneur of The Year : Captain G.R.Gopinath, & Shailendra Singh,Joint Managing Director, Percept Limited. India’s Most Admired IT Software Company : Infosys Technologies Ltd, India’s Most Admired Telecom Company : Videocon Ltd., India’s Most Admired Consumer FMCG Company : Elder Healthcare Ltd, India’s Most Admired IT Global Career Company for Masses : St Angelos Ltd., India’s Most Admired Pharmaceutical Company : Pfizer Ltd., India’s Most Promising Retail Pharmacy Company : Hetero Pharmacy., India’s Most Admired Aviation Company : Kingfisher Airlines Ltd., India’s Most Admired Legal Firm : DSK Legal., Outstanding Contribution to Indian Cinema : Yash Chopra., Media Magnet of The Year : Dr Pranoy Roy, Chairman, NDTV & Ronnie Screewala, Chairman, UTV Group, Excellen ce in Biotech Research : Biochem India Ltd. India’s Most Admired Infra-Projects Company : Unity Infra-Projects Ltd, Patil Group : India’s Most Admired Construction Group., Excellence in CSR Healthcare Services, MGM Excellence in Neutraceutical Innovation Zenova Bio – Nutrition.Excellence in CSR Healthcare Services : MGM New Bombay Hospital. ,Excellence in Neutraceutical Innovation : Zenova Bio – Nutrition.
The Conclave will also see some powerful faces to debate are Dr. Lalit S. Kanodia, Founder & Chairman. Datamatics, to talk on IT Revolution in India : Can India take keyboards to rural India?, Captain G R Gopinath: Founder Chairman, Deccan 360 Degrees, on Re-inventing AAM AADMI’S Flight : Have we missed the bus?, Rajeev Kapoor, CEO, Fiat India to speak on Luxury VS Elegance – The Future of Four Wheeler Markets in India, G.R.K. Reddy , CMD, MARG Group on “Opportunities for Corporate India in building Sustainable Regional Growth Models”., Anand Desai, Managing Partner, DSK Legal on FDI Destination: India. Huzaifa Khorakiwala, Executive Director, Wockhardt Ltd & CEO, Wockhardt Foundation on Human Values for World Peace, Agnelorajesh Athaide, CMD, St Angelos Ltd.on Computer Education for Masses, Ravi Menon : MD & Head Strategy, HSBC on “Investment Banking in India : Challenges & Opportunities, Shailendra Singh : Joint Managing Director, Percept on India on the move : Brand India & Rana Kapoor, Chairman, YES BANK LTD on “Professional Entrepreneurship in Emerging India
5. Pharmaceutical Leadership Summit & Awards ( www.pharmasummit.in ) ( India’s most awaited & credible Annual Event)
Originally launched in 1999 as the Pharma Business & Technology Excellence Awards, these were first produced by the PHARMA BUSINESS & TECHNOLOGY MAGAZINE as a means of honoring innovation in pharmaceutical marketing, corporate governance and research and development & Lifetime Achievements category. Pharma Excellence Awards were produced by PBT Awards in India and expanded to recognize global corporate citizenship and individual achievements. As PBT Magazine was discontinued, the task was taken up by the Management of Pharma Leaders Magazine. Over the Years, the awards was re-evaluated and recast to focus more on scientific accomplishments in industry and academic pharmaceutical research. The awards have been presented and at a sold-out black tie gala to over 50 industry executives and leading academic scientists from around the world joined in a moving tribute to the more than twenty winners honored that evening. PRVIOUS AWRAD WINNERS included : Late Shri Parvinder Singh, Ranbaxy –Chairman, Ranbaxy Labs Ltd, 1999, Shri Desh Bandhu Gupta,Chairman, Lupin Ltd – 1999, Shri K.Anji Reddy, Chairman, Dr Reddy’s Labs Ltd – 1999, Shri Devinder Pal, Management Consultant. 1999, Shri Samprada Singh, Chairman, Alkem Labs Ltd., Shri Ajit Singh, Chairman, ACG Worldwide, Shri I.A.Modi, Chairman, Cadila Pharmaceuticals Ltd. Shri Vikram Aima, CMD, Ochoa Labs Ltd. Shri Habil F Khorakiwala.Chairman, Wockhardt Ltd. Shri Raghavendra Rao, Chairman, Orchid Pharmaceuticals Ltd. Shri Dilip Sanghvi, CMD, Sun Pharmaceuticals Ltd.
The 2010 annual Pharmaceutical Achievement Awards recognized the significant accomplishments of individuals and organizations in the global pharmaceutical and biotechnology industries in the areas of science, business and corporate generosity. These awards have been designed with the broad support and unbiased contributions of industry and academic advisors, a well respected international accounting firm and the production team of Pharma Leaders under the supervision of Editor-In-Chief of Pharma Leaders Magazine.
Winners of 2nd Annual Pharmaceutical Leadership Summit 2009 : Excellence Awards.
1. V.S.Reddy, Managing Director, British Biologicals. (India’s most Admired Neutraceutical Company)
2. Ms Anju Gupta, Managing Director, VHB Life Sciences Ltd. (Most technically & scientifically advanced Pharmaceutical Manufacturing unit of the year).
3. S.K Singh, Managing Director, Cachet Pharmaceuticals Pvt. Ltd (Emerging Company of the year Award)
4. Dilip Surana, Managing Director, Microlabs Ltd. (Company of the Year).
5. Shri Suresh Kare, Chairman, Indoco Remedies Ltd. (Life Time Achievement Award).
6. R.C.Bhagat, Chairman, VHB Life Sciences Ltd. (Lifetime Achievement Award).
7. Samprada Singh, Chairman, Alkem Labs Ltd. (Lifetime Achievement Award)
8. Mr Manohar Kothari, Managing Director, Indo German Pharma Equip Pvt Ltd. (Life Time Achievement Award) Dr Himadri Sen,
9. President, R&D, Ranbaxy Ltd (Excellence in “NDDS”& Generics)
10. Sri Ajit Singh, Chairman & Sri Jasjit Singh,MD, ACG World Wide (Lifetime Achievement Award).
11. Sri Jagdish Saxena, Chairman & MD, Elder Pharmaceuticals Ltd (Lifetime Achievement Award).
12. Mr Malvinder Mohan Singh,Chairman,MD & CEO,Ranbaxy Ltd (Dynamic Enterpreneur of the year)
13. Sri Kaushik Desai ,Director& CEO Global Pharmatech (Excellence in Pharma Profession)
14. Dr P.M Naik, Project Director, Zydus Cadila Ltd (Excellence in Pharma Profession)
15. Dr Desh Bandhu Gupta, Chairman, Lupin Ltd (Lifetime Achievement Award).
16. Mr C.P.Bothra, Managing Director, Medreich Group (India’s Most trusted Export Company of the year)
17. Mr N.K.Singh, CMD, Galpha Labs Ltd. (India’s Fastest growing Pharmaceutical Company 09)
18. Ms Anju Gupta, MD, VHB MEDISCIENCES LTD (India’s Youngest MD & CEO)

Winners of 2nd Annual Pharmaceutical Leadership Summit 2010 : Excellence Awards.
1. Businessman of the Year 2010 Shri Malvinder Mohan Singh, Group Chairman, Fortis
2. Businesswoman of the Year 2010 - Dr.Villoo Morawala-Patell, Founder and CMD, AVESTHAGEN LIMITED
3. Dynamic Entrepreneur of the Year 2010, Shri Dilip Surana, CMD, Microlabs Ltd.
4. India’s Best Pharma OTC Company of the Year 2010- Abbott Ltd
5. India’s Best Nutrition & Neutraceuticals Co of the Year 2010 - Dr Anjali Mukerjee’s Health Total
6. Best Pharma Company of the Year 2010 - Abbott Ltd,
7. Pharma CSR Organisation of the Year 2010. Wockhardt Foundation
8. Pharma Professional of the Year 2010 - , Shri Tapan Ray, Director-General, OPPI. Shri Kewal Handa, MD, Pfizer & Wyeth Ltd. Shri Deepak Naik, Managing Director, Eisai Pharma Ltd
9. Lifetime Achievement Award of 2010. Dr.Y K Hamid, Chairman Cipla Ltd,Shri Samprada Singh, Alkem Labs Ltd. Shri I.A.Modi, Chairman,Cadila Pharmaceuticals Ltd. Shri Joseph D’souza, Chairman, Oswolrld. Best Brand of the Year 2010. Volini & Revital,
10. Best Company in R & D Excellence 2010 - , Bharat Biotech International Ltd.
11. India's Most Admired Surgeon Of the Year 2010, Dr Ramakant Panda, VC, Asian Heart Institute
12. India's Fastest growing retail Pharmacy Chain 2010 Trust Chemists & Druggists Ltd
13. Excellence in Pharmacy Profession of the Year 2010 Dr Bharatesh R Jagashetty, Drug Controller of Karnataka
14. Excellence Innovators in Blood and Biological Products of the Year 2010 Synergy Diagnostics Pvt Ltd India's Most Watched Company of the Year 2010 Elder Pharmaceuticals Ltd.
15. Company of the Year 2010 (SME) Galpha Laboratories Ltd
16. Excellence in Bulk Drug and Exports, Hetro Drugs Ltd
17. Emerging Company of the Year 2010 Samarth Pharma Pvt Ltd
18. India’s Most Admired Pharma Company of the year 2010 Pfizer Ltd
19. Hottest Exports Company of the Year 2010, Bry Air Asia Pvt Ltd
20. Research Scientist of the year 2010, Dr Rashmi Barbhaiya, CEO & MD, Advinus Therepeutics Ltd, Computer Literacy Programs for Masses - ST ANGELOS COMPUTER LTD.